Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

Completed

Conditions studied: Invasive Pneumococcal Disease

In brief

This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.

Key facts

Study ID

NCT01128439

Run by

Pfizer

People needed

1

Starts

2010-07-01

Expected to finish

2015-04-01

Last updated by the study team

2018-12-04

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented invasive pneumococcal disease (IPD), defined as recovery of an isolate of S pneumoniae from a normally sterile site in a member of the surveillance population.

You may not qualify if…

• None

Where it is running

• Kaiser Permanente Vaccine Study Center — Oakland, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.